Publication

Article

Supplements

Advances in ADHD Management
Volume

Data Shows Disparities in Mental Health Treatments Among Pediatric Populations

Author(s):

These disparities were noted between age groups, sex, race/ethnicity, and urbanization level of residence.

Benjamin Zablotsky, PhD

Benjamin Zablotsky, PhD

In 2016, about 16.5% of US children had been diagnosed with a mental health disorder. Such common diagnoses included ADHD, anxiety, and behavioral disorders.

A new data brief from the National Center for Health Statistics (NCHS) reported on 2019 trends in mental health treatment among children aged 5-17 years. The investigators uncovered 4 major findings in their analysis, which underscored associations between treatment likelihood and key demographic characteristics such as age, sex, race/ethnicity, and level of urbanization.

Benjamin Zablotsky, PhD, and Emily Terlizzi, MPH, of the NCHS used data from the 2019 National Health Interview Survey, a nationally representative household survey of the US population, to determine the prevalence of mental health treatments among school-aged children.

They found that 13.6% of the prespecified population had received treatment in the past 12 months. Furthermore, 10.0% of children had received counseling or therapy from a mental health professional, and 8.4% had taken prescription medication for their mental health.

Additionally, their analysis showed that the prevalence of treatment was greater in older children, defined as ages 12-17 years—compared with younger children, 5-11 years (16.8% vs 10.8%, respectively).

Older children were also more likely to have taken medication for their mental health (10.9% vs 6.2%, respectively) and to have received counseling or therapy from a mental health professional (12.5% vs 7.8%, respectively) in the same time period.

The report also indicated that 14.8% of boys received any mental health treatment compared with 12.4% of girls.

Boys (9.8%) were more likely than girls (7.0%) to have been treated with medication, but there was no significant difference in use of counseling by a health care professional.

In terms of race/ethnicity, more non-Hispanic white children (17.7%) had received any health treatment compared with Hispanic (9.2%) and non-Hispanic black (8.7%) children.

This trend was also consistent in use of medication and reception of counseling or therapy. In fact, non-Hispanic white children were more than twice as likely (11.4%) to have taken medication than Hispanic (4.7%) and non-Hispanic black (5.6%) children.

And finally, the investigators found that the percentage of mental health treatment increased as urbanization decreased. For example, 12.4% of children in large metropolitan areas received treatment as compared with 17.0% in nonmetropolitan areas.

This trend was similar in terms of medication use — 7.4% in large metropolitan areas versus 11.8% in nonmetropolitan areas. There was no observed significant difference in receipt of counseling or therapy.

Zablotsky and Terlizzi noted that several of these findings, most notably in the domain of race/ethnicity and level of urbanization, were consistent with prior studies on prescription or counseling usage among children

The report, “Mental Health Treatment Among Children Aged 5–17 Years: United States, 2019,” was published online in the NCHS Data Brief.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.